论文部分内容阅读
目的探讨他汀类药物治疗对急性冠脉综合征(ACS)患者载脂蛋白及炎症水平的影响。方法选择90例确诊为ACS的住院患者,入院后即刻给予阿托伐他汀(立普托)40 mg口服。分别在入院时、治疗1个月后检测血脂、载脂蛋白(ApoA1、ApoB)及C反应蛋白(CRP)水平,观察阿托伐他汀治疗后血脂及CRP水平的变化。结果与治疗前比较,ACS患者阿托伐他汀治疗后,总胆固醇、低密度脂蛋白胆固醇均下降(P均<0.05),ApoA1水平明显升高(P<0.01),ApoB水平下降(P<0.05),CRP降低幅度更加明显(P<0.01);甘油三酯有降低趋势,高密度脂蛋白胆固醇稍有升高,但差异均无统计学意义(P均>0.05)。结论 ACS患者早期应用阿托伐他汀可改善脂蛋白代谢并减轻炎症反应。
Objective To investigate the effect of statins on apolipoprotein and inflammation in patients with acute coronary syndrome (ACS). Methods Ninety hospitalized patients diagnosed with ACS were randomized to receive atorvastatin (Lipitor 40 mg) orally immediately after admission. Serum lipids, apolipoproteins (ApoA1, ApoB) and C-reactive protein (CRP) levels were measured at admission and 1 month after treatment, and the changes of blood lipids and CRP levels were observed after atorvastatin treatment. Results Compared with before treatment, total cholesterol and low density lipoprotein cholesterol were decreased (P <0.05), ApoA1 level was significantly increased (P <0.01), ApoB level was decreased (P <0.05) ), CRP decreased more significantly (P <0.01); triglycerides decreased, HDL cholesterol slightly increased, but the difference was not statistically significant (P all> 0.05). Conclusions Early use of atorvastatin in patients with ACS can improve lipoprotein metabolism and reduce inflammation.